Investor directory

Fund+

Fund+ is a venture capital firm established in 2015 and located in Leuven, Belgium. The firm specializes in investing in startup and early-stage companies within the life sciences sector, focusing on diagnostics, therapeutics, and medical devices. Fund+ aims to create sustainable shareholder value while contributing to the advancement of the life sciences industry and generating a positive societal impact. The firm typically invests between EUR 3 million and EUR 8 million in advanced development stage companies, seeking to acquire significant minority stakes ranging from 10% to 20%. Fund+ primarily targets investments in developed European markets, with decisions regarding investments made by its Management Committee or Board of Directors based on the amount invested.

Focus

TherapeuticsScale StageSeries BSeries AEarly VentureShow more
http://fundplus.be
https://crunchbase.com/organization/fund
https://facebook.com/fundplus
https://linkedin.com/company/fund-
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=311161986

Jan Van den Bossche

Partner

Chris Buyse

Managing Partner

Louis Declerck

Associate

Philippe Monteyne

Partner

Alexandra Tolia

Partner

35 past transactions

Promethera Biosciences

Series C in 2016
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

TargED Biopharmaceuticals

Series A in 2022
TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.

ExeVir Bio

Series A in 2020
ExeVir Bio BV develops single-domain antibody-based therapies that help patients ward off viral infections. It develops VHH72-FC, that binds to a highly conserved region on the spikes of SARS-CoV-2, which are essential for the virus to enter the cell. The company was founded in 2020 and is based in Zwijnaarde, Belgium.

EyeD Pharma

Venture Round in 2021
EyeD Pharma SA, a pharmaceutical company, develops and commercializes ophthalmology drug products. The company is based in Liège, Belgium.

Minoryx

Series C in 2022
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Egle Therapeutics

Series A in 2021
Egle Therapeutics SAS, a biotechnology company, develops immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases. It develops Treg modulating drug pipeline, which includes computationally designed resurfaced IL-2 proprietary variants to engage or dis-engage Tregs. The company was founded in 2020 and is based in Paris, France.

Aelin Therapeutics

Series A in 2017
Aelin Therapeutics NV develops antibiotics and therapeutics using the Pept-in technology. The company's technology platform harnesses protein aggregation to induce functional knockdown of a target protein. The company's products have applications against Methicillin-resistant Staphylococcus aureus (MRSA) and undruggable targets in humans. The company was founded in 2017 and is headquartered in Heverlee, Belgium.

ITeos Therapeutics

Series A in 2012
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Ona Therapeutics

Series A in 2020
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.

OCTIMET Oncology

Series A in 2017
OCTIMET oncology’s overall strategy is to advance the development of discovery stage molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy.

Minoryx

Private Placement in 2018
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Immunic Therapeutics

Series A in 2017
Immunic is a developer of oral drugs intended to help in the treatment of chronic inflammatory diseases. The company's drugs help to develop a small molecule immune modulators that block T helper type 1- and type 17-mediated immune and build autoimmune responses to treat conditions including inflammatory bowel disease (IBD) or psoriasis, enabling physicians to treat their patients in an enhanced way.

Minoryx

Series B in 2018
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

ITeos Therapeutics

Series B in 2018
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

ITeos Therapeutics

Series B in 2020
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

EyeD Pharma

Private Placement in 2019
EyeD Pharma SA, a pharmaceutical company, develops and commercializes ophthalmology drug products. The company is based in Liège, Belgium.

Tubulis

Series B in 2024
Tubulis GmbH researches, designs, and develops protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. The company develops transformative antibody-drug conjugates (ADCs), which helps to identify novel protein-drug combinations for therapeutic application. The company was founded in 2019 and is based in Munich, Germany.

AstriVax

Seed Round in 2022
AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.

Novadip Biosciences

Series B in 2021
Novadip Biosciences SA is a biopharmaceutical company that develops process and distribution platform for tissue regeneration. It focuses on autologous cell therapies for critical size tissue reconstruction; allogeneic therapeutics for smaller and prevalent tissue defects; and miRNA/exosome-based therapeutics for systemic tissue and other diseases. The company was founded in 2013 and is based in Mont-Saint-Guibert, Belgium.

Tubulis

Series B in 2022
Tubulis GmbH researches, designs, and develops protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. The company develops transformative antibody-drug conjugates (ADCs), which helps to identify novel protein-drug combinations for therapeutic application. The company was founded in 2019 and is based in Munich, Germany.

EyeD Pharma

Funding Round in 2019
EyeD Pharma SA, a pharmaceutical company, develops and commercializes ophthalmology drug products. The company is based in Liège, Belgium.

Confo Therapeutics

Private Placement in 2019
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.

Cardior Pharmaceuticals

Series B in 2021
Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the treatment and prevention of heart disease. It focuses on developing CDR-132X, an oligonucleotide-based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress or injury. Cardior Pharmaceuticals is a planned academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world.

Immunic Therapeutics

Private Placement in 2019
Immunic is a developer of oral drugs intended to help in the treatment of chronic inflammatory diseases. The company's drugs help to develop a small molecule immune modulators that block T helper type 1- and type 17-mediated immune and build autoimmune responses to treat conditions including inflammatory bowel disease (IBD) or psoriasis, enabling physicians to treat their patients in an enhanced way.

eTheRNA immunotherapies

Series B in 2022
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

Ona Therapeutics

Private Placement in 2020
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.

Confo Therapeutics

Series A in 2019
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.

Horama SAS

Series B in 2017
Horama SAS focuses on the development of gene therapy products to rare ophthalmology pathologies with recombinant adeno-associated viral vectors for orphan blinding diseases. Its gene therapy products target retinal dystrophies and retinopathies. The company was founded in 2014 and is headquartered in Paris, France.

ITeos Therapeutics

Private Placement in 2020
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Horama SAS

Private Placement in 2017
Horama SAS focuses on the development of gene therapy products to rare ophthalmology pathologies with recombinant adeno-associated viral vectors for orphan blinding diseases. Its gene therapy products target retinal dystrophies and retinopathies. The company was founded in 2014 and is headquartered in Paris, France.

ITeos Therapeutics

Private Placement in 2018
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Indigo Diabetes

Private Placement in 2020
Indigo Diabetes nv (Indigo) is a young high-tech medical device company founded by Danaë Delbeke and her team ended in 2016. Indigo develops the world’s first invisible sensor for people living with diabetes to address their need for accurate glucose monitoring with improved user experience. Indigo exploits groundbreaking photonics technology that revolutionized the Internet during the last decades and now aims at transforming diabetes management.

eTheRNA immunotherapies

Series B in 2020
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

eTheRNA immunotherapies

Private Placement in 2020
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

Novadip Biosciences

Series B in 2022
Novadip Biosciences SA is a biopharmaceutical company that develops process and distribution platform for tissue regeneration. It focuses on autologous cell therapies for critical size tissue reconstruction; allogeneic therapeutics for smaller and prevalent tissue defects; and miRNA/exosome-based therapeutics for systemic tissue and other diseases. The company was founded in 2013 and is based in Mont-Saint-Guibert, Belgium.